Back to Search
Start Over
CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
- Source :
-
Clinical Journal of Oncology Nursing . Dec2022, Vol. 26 Issue 6, p597-601. 5p. 3 Charts. - Publication Year :
- 2022
-
Abstract
- Cellular immunotherapy with CD19-directed chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape for aggressive B-cell non-Hodgkin lymphoma (B-NHL). Three CAR T-cell therapies are commercially available for the treatment of large B-cell lymphoma. This article reviews a case study to highlight a typical treatment journey for a patient with relapsed large B-cell lymphoma undergoing cellular immunotherapy, including treatment timeline and toxicities, as well as implications for advanced practice providers caring for patients with B-NHL. [ABSTRACT FROM AUTHOR]
- Subjects :
- *PATIENT aftercare
*OCCUPATIONAL roles
*NEUROTOXICOLOGY
*SYNDROMES
*CELLULAR therapy
*CELL receptors
*B cell lymphoma
*CANCER relapse
*TREATMENT effectiveness
*CONTINUUM of care
*CYTOKINE release syndrome
*MEDICAL referrals
*HEALTH care teams
*COMMUNICATION
*NURSES
*INDEPENDENT living
*T cells
*NURSE practitioners
*REHABILITATION
*IMMUNOTHERAPY
*ANTIGENS
*SYMPTOMS
*MIDDLE age
Subjects
Details
- Language :
- English
- ISSN :
- 10921095
- Volume :
- 26
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Clinical Journal of Oncology Nursing
- Publication Type :
- Academic Journal
- Accession number :
- 160356534
- Full Text :
- https://doi.org/10.1188/22.CJON.597-601